Clinical Trials

37 enrolled 8 charts

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

6 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

520 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04159142 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

414 enrolled

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

150 enrolled

Triple Negative Breast Neoplasms

NCT05582538 2025-08-24

ATRiBRAVE

37 enrolled

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

29 enrolled 11 charts

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01525966 2025-03-03

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT06538896 2024-11-26

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

20 enrolled

Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

139 enrolled

Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03121352 2023-10-06

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

30 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

35 enrolled

Triple Negative Breast Neoplasms

NCT05233696 2022-12-06

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03907800 2022-10-27

NeoPATH

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04129996 2022-01-11

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

46 enrolled

Triple Negative Breast Neoplasms

NCT05068141 2021-10-15

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

79 enrolled

Triple Negative Breast Neoplasms

NCT03289819 2021-04-08

NIB

53 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00733408 2018-12-04

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

59 enrolled 14 charts